Significance of Osteopontin Expression in Human Invasive Breast Tumour Stroma

Lígia R. Rodrigues*, a, Nair Lopesb, Bárbara Sousa b, Daniella Vieirac, Fernanda Milanezb, Marie Paulsson a, Helena Lindmark-Mänsson d,e, José A. Teixeira a, Fernando Schmitt b,f

aIBB – Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, Universidade do Minho, 4710-057 Braga, Portugal
bInstituto de Patologia e Imunologia Molecular – IPATIMUP, Universidade do Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
cDepartamento de Patologia/Universidade Federal de Santa Catarina, Serviço de Anatomia Patológica/Hospital Universitário da Universidade Federal de Santa Catarina, Florianópolis, Brasil
dDepartment of Food Technology, Engineering and Nutrition, Lund University, P.O. Box 124, S-221 00, Lund, Sweden
e Swedish Dairy Association, Scheelevägen 18, SE-223 63 Lund, Sweden
f Faculdade de Medicina, Universidade do Porto, Al. Prof. Hernâni Monteiro 4200 - 319 Porto, Portugal

Abstract: Osteopontin has been reported to stimulate cell adhesion, migration and specific signalling functions. Its overexpression has been found in melanoma, breast, lung, colorectal, stomach and ovarian cancer. However, its overexpression and role in human breast cancer remains to be elucidated. In this study, invasive breast tumours from 129 patients were examined by immunohistochemistry in order to assess osteopontin association with several molecular tumour markers. Additionally, its relationship with proliferation and angiogenesis was determined. Ultimately, other tumour variables such as histological grade, tumour size and nodal status were also assessed. Results achieved showed that no statistical significant association exists between osteopontin expression and major clinicopathological parameters or angiogenesis, except for the number of lymph nodes involved. However, a correlation with some molecular markers was observed, namely with P-Cadherin, EGFR, cytokeratin 14 and vimentin. Additionally, higher proliferation rates were found for the tumours expressing osteopontin. Although several studies refer osteopontin as a potential breast cancer biomarker, it is still not clear if it can provide important diagnosis information, evaluate treatment effects or assess the potential for metastatic disease in patients.

Keywords: Osteopontin, tumour stroma, invasive breast cancer.

INTRODUCTION

Cancer biomarkers that allow the anticipation of the outlines of disease have been an emerging issue and there is a growing need for additional reliable molecular markers [1]. Osteopontin (OPN) is a phosphorylated glycoprotein found in all body fluids, extracellular matrix components, and proteinaceous matrix of mineralized tissues [2-4]. This protein was found to be overexpressed in tumours and serum of women with ovarian cancer, and was correlated with progression [5, 6]. Furthermore, OPN has been detected in approximately 90% of primary breast carcinomas [7, 8], and recent studies demonstrated that its overexpression is also related with breast cancer evolution and metastasis [2, 9]; therefore there is a potential utility of OPN in monitoring disease status in breast cancer patients [10].

In human tissues, OPN has been found to be produced by epithelial cells of the gastrointestinal, urinary and reproductive tracts, the gallbladder, pancreas, lung bronchi, lactating breast, salivary glands and sweat ducts [11]. OPN was localized to the luminal surfaces in these sites, and also in human secretions including blood, milk and urine [10, 12]. Overall these findings suggested that OPN may have a protective role in interactions between epithelial surfaces and the external environment. Nevertheless, several studies have described a link between OPN and cancer in the past years [9, 10, 13, 14]. Presently, it is fully accepted that OPN expressed by tumour cells alters their malignant properties, specifically by affecting their ability to grow, invade and metastasize. However, as OPN is known to be expressed in both normal and malignant tissues, an elucidation on its significance in human cancer is required.

The association of OPN with breast tumour progression was studied by Tuck and co-workers [15] using samples from a patient who had bilateral mammary carcinomas of similar histology and later developed metastatic recurrence. Their findings suggest that OPN, both in tumour cells and in
plasma, may be a marker for tumour aggressiveness in breast cancer, and elevated levels in a primary tumour may predict the future development of metastasis. Furthermore, the same group studied the expression of OPN mRNA and protein in the tumours of 154 women with lymph node negative (LNN) breast cancer [16]. Results gathered in this study support the idea that OPN levels within tumour cells may be a useful predictor of patient outcome in breast cancer, and also that OPN may play a functional role in tumour progression and aggressiveness. A correlation between OPN expression and an increased invasiveness or metastatic potential has also been reported in other human tumours, such as melanoma, breast, lung, colorectal, stomach and ovarian cancer [2, 4, 10, 17].

Some studies have also reported an implicated OPN in angiogenesis, nevertheless many of the results remain circumstantial and further clarification on the details of this possible role is required [18, 19]. The association of OPN to this process is a consequence of its ability to bind the ανβ3 integrin, which in turn is a marker of angiogenesis and expressed by neovascular endothelial cells [19].

Recently, Finak and co-workers [20] reported the presence of OPN in the breast tumour stroma associated with a poor outcome cluster of genes linked to angiogenic, hypoxic and tumour-associated macrophage responses. Under normal physiological conditions, stroma serves as an important barrier to epithelial cell transformation; the interplay between epithelial cells and the microenvironment maintains epithelial polarity and modulates growth inhibition [21]. However, the stromal compartment undergoes changes in response to emerging epithelial lesions and can have a key role in cancer initiation and progression [21, 22]. These changes may include the recruitment of immune endothelial cells providing growth and matrix remodelling factors, as well as a new blood supply promoting tumour growth and metastasis [21-23].

The aim of the present study was to examine by immunohistochemistry (IHC) on tissue microarrays (TMAs), the OPN expression in invasive tumour stromas from 129 patients in order to assess its association with several molecular tumour markers (ER (estrogen receptor), HER2 (human epidermal receptor 2), CK5 (cytokeratin 5), CK14 (cytokeratin 14), CK8/18 (cytokeratin 8/18), p63, P-CD (P-cadherin), EGFR (epidermal growth factor receptor), PgR (progesterone), VIM (vimentin)). Additionally, the relationship of OPN with proliferation (Ki67) and angiogenesis (CD105 - endoglin) was determined. Ultimately, other tumour variables such as histological grade, tumour size and nodal status were also assessed.

### MATERIALS AND METHODOLOGY

#### Patients’ Selection

One hundred and twenty nine tumour samples were obtained from patients treated at the Federal University of Santa Catarina, Florianopolis-SC, Brazil and kindly given to us for this work. Of these, 22 tumours presented clinical features of familial breast cancer according to the Breast Cancer Linkage Consortium [24, 25], 96 tumours were from patients without any clinical familial feature (sporadic) and 11 tumours had no clinical data available to determine if they have clinical features of familial breast cancer.

#### Tissue Microarray Construction

Representative areas of the invasive breast carcinomas were carefully selected on hematoxylin and eosin (H & E) – stained sections and marked on the correspondent individual paraffin blocks. Two tissue cores (2 mm in diameter) were obtained from each selected specimen and precisely deposited into a recipient paraffin block using TMA workstation (TMA builder ab1802, Abcam, Cambridge, UK). Eighteen TMA blocks were constructed, each containing 24 tissue cores, arranged in a 4x6 sector. In each TMA block, nonneoplastic breast and testicular tissue cores were also included as controls and TMA guide, respectively. After construction, a

### Table 1. Antibodies Used in the Immunohistochemistry Study

<table>
<thead>
<tr>
<th>Molecular Marker</th>
<th>Antibody</th>
<th>Origin</th>
<th>Clone</th>
<th>Dilution</th>
<th>Antigenic Retrieval (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ER</td>
<td>Rmab</td>
<td>Neomarkers, USA</td>
<td>SP1</td>
<td>1:150</td>
<td>30</td>
</tr>
<tr>
<td>HER2</td>
<td>Rmab</td>
<td>Neomarkers, USA</td>
<td>SP3</td>
<td>1:80</td>
<td>30</td>
</tr>
<tr>
<td>CK5</td>
<td>Mmab</td>
<td>Neomarkers, USA</td>
<td>XM26</td>
<td>1:50</td>
<td>30</td>
</tr>
<tr>
<td>p63</td>
<td>Mmab</td>
<td>Neomarkers, USA</td>
<td>4A4</td>
<td>1:150</td>
<td>30</td>
</tr>
<tr>
<td>P-CD</td>
<td>Mmab</td>
<td>BD Transduction, KY, USA</td>
<td>56</td>
<td>1:50</td>
<td>30</td>
</tr>
<tr>
<td>EGFR</td>
<td>Mmab</td>
<td>Zymed, USA</td>
<td>31G7</td>
<td>1:100</td>
<td>30</td>
</tr>
<tr>
<td>CK14</td>
<td>Mmab</td>
<td>Novocastra, UK</td>
<td>LL002</td>
<td>1:400</td>
<td>30</td>
</tr>
<tr>
<td>CK8/18</td>
<td>Mmab</td>
<td>Zymed, USA</td>
<td>UCD/PR-10.11</td>
<td>1:50</td>
<td>40</td>
</tr>
<tr>
<td>PgR</td>
<td>Rmab</td>
<td>Neomarkers, USA</td>
<td>SP2</td>
<td>1:300</td>
<td>30</td>
</tr>
<tr>
<td>VIM</td>
<td>Mmab</td>
<td>DakoCytomation</td>
<td>V9</td>
<td>1:150</td>
<td>30</td>
</tr>
<tr>
<td>Ki67</td>
<td>Rmab</td>
<td>Neomarkers, USA</td>
<td>SP6</td>
<td>1:300</td>
<td>30</td>
</tr>
<tr>
<td>OPN</td>
<td>Mmab</td>
<td>Santa Cruz, USA</td>
<td>AKm2A1</td>
<td>1:500</td>
<td>30</td>
</tr>
<tr>
<td>CD105</td>
<td>Mmab</td>
<td>Novocastra, UK</td>
<td>4G11</td>
<td>1:50</td>
<td>30</td>
</tr>
</tbody>
</table>

Mmab – mouse monoclonal antibody; Rmab – rabbit monoclonal antibody.
μm tissue sections were cut and adhered to Superfrost Plus glass slides. An H & E – stained section from each block was reviewed to confirm the presence of morphological representative areas of the initially identified lesions. All the markers were assayed in TMAs, except for CD105 (endoglin) that was assayed using whole tissue sections of each case.

**Immunohistochemistry**

Immunohistochemical staining for ER, HER2, CK8/18, VIM, CK5, p63, OPN, LF and CD105 was performed using the streptavidin-biotin-peroxidase technique (LabVision Corporation, Fremont, CA, USA) in each set of 18 glass slides comprising the TMAs, whereas P-CD, CK14, EGFR, Ki67 and PgR used the HRP labelled polymer (DakoCytomation, Carpinteria, CA, USA).

Antigen unmasking for p63, ER, HER2, OPN, VIM, PgR, Ki67 and CD105 was carried out using a dilution of 1:100 from a commercially available solution of citrate buffer, pH=6.0 (Vector Laboratories, Burlingame, CA, USA) at 98°C, whereas a dilution of 1:10 from tris-ethylenediaminetetraacetic (EDTA) solution with pH=9.0 (DakoCytomation) was used for CK5, P-CD and CK14.

Epitope retrieval for EGFR was performed by proteolytic enzyme digestion (pepsin A, 4 g/l; Sigma-Aldrich, Germany) at 37°C, and for CK8/18 a solution of PT Module Buffer (LabVision) was used.

The antigen retrieval times, antibodies, dilutions and suppliers are listed in Table 1. After washes in a phosphate buffer solution (PBS), endogenous peroxidase activity was blocked by incubation of the slides in a 3% hydrogen peroxide (Panreac, Spain) in methanol (Sigma-Aldrich). The slides were incubated with a blocking serum (LabVision) for 15 min and then incubated with the specific antibody.

Primary antibody incubation was performed for 30 minutes at room temperature (ER, HER2, PgR, CK8/18 and VIM), for 1h at room temperature (P-CD, p63, CK5, EGFR, CK14, Ki67 and OPN) or overnight at 4°C (CD105). After washes, the slides were incubated with biotinylated secondary antibody, followed by streptavidin-conjugated peroxidase (LabVision). Diaminobenzidine (DAB) was used as a chromogen (DakoCytomation).

For P-CD, CK14, EGFR, Ki67 and PgR staining, the secondary antibody was associated with HRP labelled polymer (DakoCytomation) and immediately revealed with DAB. Tissues were then counterstained with Mayer’s hematoxylin, dehydrated and coverslipped using a permanent mounting solution (Zymed, San Francisco, CA, USA).

Positive controls were included in each run in order to guarantee the reliability of the assays. Nonneoplastic breast tissue cores, as well as normal breast surrounding the neoplastic cells, were considered internal controls for most of the antibodies tested: p63, CK5, CK14, P-CD, EGFR (myoepithelial cells); ERα, PgR, CK8/18 (epithelial cells); VIM (stromal cells). The evaluation of immunohistochemistry results was done by two pathologists (F. Schmitt and F. Milanezi), as follows: P-CD was considered positive whenever more than 10% of the neoplastic cells showed membrane staining, usually associated to cytoplasmic staining [26]; similarly, we adopted the same cutoff value for nuclear ERα and PgR reactivity.
examined the relationship between OPN expression in tumour stroma and the other molecular markers tested, as well as with other tumour variables such as size, nodal status and histological grade. From a total of 129 cases immunohistochemically interpretable, we found that 43.4% of the cases showed a positive staining for OPN in the tumour stroma (Table 2). Among the OPN positive cases, the distribution of cancer subtypes found was 50.0% Luminal A, 5.4% Luminal B, 23.2% Basal and 17.9% HER2-overexpressing tumours (p=0.304) (Table 4). Moreover, regarding cancer subtype, it can be seen from Table 4 that cases negative for OPN showed higher percentages of Luminal A (57.5%) tumours as compared with the positive ones. Significant statistically differences between the two groups (OPN positive and OPN negative) were observed for few of the studied molecular markers, such as P-CD (p=0.032), EGFR (p=0.077), CK14 (p=0.066) and VIM (p=0.069). OPN positive tumours presented mainly histological grade I and II (30.4% and 43.5%, respectively) and demonstrated a higher frequency of P-CD and VIM expression (44.6% and 19.6%, respectively) as compared to OPN negative tumours (no statistical significance was although observed, p=0.941). On the other hand, cases negative for OPN showed mainly histological grade II (46.5%) and higher frequency of cases ER-positive, PgR-positive and P-CD-negative (64.4%, 41.1% and 73.6%, respectively).
Osteopontin Expression in Tumour Stroma

Fig. (1). Expression of proteins and H&E staining of the core represented in each marker studied by IHC on TMA. All TMA cores represent neoplastic tissue with a strong staining pattern. Except for cases d2, e2, f2, i2 and l2 where it was used an original magnification of X630, for all the others it was used X400: (a1, a2) – (H&E, ER staining); (b1, b2) – (H&E, HER2 staining); (c1, c2) – (H&E, CK5 staining); (d1, d2) – (H&E, p63 staining); (e1, e2) – (H&E, P-CD staining); (f1, f2) – (H&E, EGFR staining); (g1, g2) – (H&E, CK14 staining); (h1, h2) – (H&E, CK8/18 staining); (i1, i2) – (H&E, PgR staining); (j1, j2) – (H&E, VIM staining); (l1, l2) – (H&E, Ki67 staining); (m1, m2) – (H&E, CD105 staining); (n1, n2) – (H&E, OPN stroma staining).
respectively). A low expression of basal markers was observed for both groups (OPN positive and OPN negative). Microvessel density is regarded as a surrogate marker for angiogenesis and has been used for tumour prognosis. In this study, microvessel density was identified immunohistochemically using a monoclonal antibody against CD105 (endoglin) in invasive breast cancer tissue sections. The expression of CD105 in the microvessels within both groups, OPN-positive (mean 26 ± 9 microvessels/mm²; range 9-47) and OPN-negative (mean 24 ± 10 microvessels/mm²; range 9-72), was similar and no statistical significant difference was observed (p=0.298).

Regarding the Ki67 proliferation indices (indicator of prognosis in breast cancer), a strong statistical difference (p=0.001) could be observed between OPN-positive and negative groups. Higher Ki67 proliferation indices (> 20%) could be observed between OPN-positive and negative groups. Higher Ki67 proliferation indices (> 20%) were detected for the OPN-positive group (56.4%) (Table 4).

Regarding tumour size (Table 4), we observed that OPN-positive cases showed higher frequencies of tumours between 2 and 5cm (53.7%), whereas cases OPN-negative showed higher frequencies of T1 (smaller than 2cm) (35.3%) (p=0.572). Additionally, we found that the cases OPN-negative showed a higher number of lymph nodes involved (>3) as compared to the cases OPN-positive (Table 4) (p=0.107).

**DISCUSSION**

The purpose of this work has been to establish, using immunohistochemical techniques, the level of expression of the glycoprotein OPN in the stroma of human invasive breast carcinomas and its clinical significance. We have found that 43.4% of the carcinomas are stained positively for OPN by the mouse monoclonal antibody to human OPN (mAB clone Akm2A1), which is slightly below the overall staining levels previously reported with other antibodies, namely with a monoclonal antibody mAB 53 prepared against the recombinant GST-human OPN fusion protein, or with a rabbit polyclonal antibody to human OPN (70-80%). The mAB Akm2A1 antibody used in this study as proven to be very specific for OPN, especially for endometrial carcinomas [7, 15, 16, 25, 28, 34, 35]. As referred previously and in agreement with other reports [9, 10, 16, 36], the staining in specimens is not restricted to carcinoma cells, because variable, often reduced levels are detected in normal parenchymal breast tissue and in some reactive fibroblast-like cells, macrophages, lymphocytes and blood vessels [37, 38]. Furthermore, OPN was recently found in the breast cancer stroma [20] associated with a poor outcome cluster of genes linked to angiogenic, hypoxic and blood vessels [37, 38]. As referred previously and in agreement with other reports [9, 10, 16, 36], the staining in specimens is not restricted to carcinoma cells, because variable, often reduced levels are detected in normal parenchymal breast tissue and in some reactive fibroblast-like cells, macrophages, lymphocytes and blood vessels [37, 38]. As referred previously and in agreement with other reports [9, 10, 16, 36], the staining in specimens is not restricted to carcinoma cells, because variable, often reduced levels are detected in normal parenchymal breast tissue and in some reactive fibroblast-like cells, macrophages, lymphocytes and blood vessels [37, 38]. Furthermore, OPN was recently found in the breast cancer stroma [20] associated with a poor outcome cluster of genes linked to angiogenic, hypoxic and tumour-associated macrophage responses. Contrary to previous published results [16, 29, 39], in this study no significant association could be observed between OPN expression and tumour variables such as nodal status (p=0.107) and tumour size (p=0.572). Nevertheless, these results are in accordance with those published by Kim and co-workers [28] that also failed to find an association of immunohistochemical staining for OPN and any clinicopathological parameters in 253 cases of breast cancer. In their study, 87% of the patients exhibited OPN-positive carcinomas, which is considerably higher than other reports. This higher proportion was found to be a consequence of using a polyclonal antibody to human OPN that recognizes an extra Mr 45, 000 polypeptide in extracts of breast cancers, and therefore this number of positive cases was overestimated. Furthermore, Ribeiro-Silva and co-workers [40] also studied OPN expression in invasive breast cancers and couldn't correlate it with several markers and clinicopathological features, such as grading and tumour size. In addition, also no correlation between OPN expression and basal-like phenotype was found. It is important to notice that although several studies have been published recently on the involvement of OPN in breast cancer (and other types of cancer) [2, 15, 16, 20, 28, 29], it is not straightforward to compare the results obtained by different researchers. Some of these studies were performed using cell lines [2, 37], plasma [2] or paraffin blocks of tumours [16, 28, 29, 37]. Moreover, these studies focus on parameters such as disease free and patient survival, that were not included in our study. In addition, the most commonly reported markers are p53, ER and PR. Therefore, some of the molecular markers used in our work have never been studied together with OPN.

The fact that there is no significant correlation between the presence of OPN and major pathological tumour variables associated with poor patient prognosis as lymph node metastasis and tumour size, may reflect the characteristics of the tumours in this group of patients (54.3% luminal-type A and 16.3% basal-type), as well as the size of the sample. Patients with luminal-type A tumours have the most favourable prognosis, whereas patients with basal-type tumours have worst prognosis [41]. Our results are in accordance with the work described by Rudland and co-workers [29], as they state that the association of OPN with worse prognosis appears to be independent of nodal status and other established clinical prognostic indicators. In our study, a minority (16.4%) of the tumours are classified as T3; this is a small fraction in comparison with other groups of patients [42]. Moreover, nodal status has been undertaken on only 62.3% of the tumours. These smaller numbers may be responsible for the less meaningful associations.

Additionally, several molecular markers were tested for association with immunohistochemical staining for OPN in human invasive breast carcinomas, however only P-CD, EGFR, CK14 and VIM, showed statistical significance.

As in other types of carcinomas, transformation of the normal breast epithelium into an invasive malignancy is the result of multiple steps. These steps consist of transformation of normal to an atypical hyperplastic epithelium with a subsequent high risk of progression to intraductal carcinoma, followed in some cases by invasion into the stroma [43]. A basic feature of normal breast histology is the maintenance of specific adhesive relationships between epithelial cells, between epithelial and myoepithelial cells, and between cells and the extracellular matrix. Disruption or deregulation of these adhesive relationships causes a loss of ductal and lobular architecture and accompanies neoplastic transformation. Furthermore, progression to malignant phenotypes involves local invasion and metastasis, two processes in which cell-cell and cell-extracellular matrix adhesions are altered. The mechanism of OPN overexpression and its role in human breast cancer is not clear. Although it is generally accepted that OPN occurs in the carcinoma cells themselves, the relative proportion sequestered from host cells such as activated macrophages and/or lymphocytes, and that is produced in situ has varied considerably [27, 36], but at least a sizeable proportion is now be-
Osteopontin Expression in Tumour Stroma

The Open Breast Cancer Journal, 2009, Volume 1

...to bind.

The association of OPN with this process is a consequence of its ability to bind integrins, which in turn, is a marker of angiogenesis and is expressed by neovascular endothelial cells [3, 10, 18, 37]. Nevertheless, in this study no significant difference could be observed between OPN-positive and -negative cases regarding angiogenesis.

Endoglin has been reported to be upregulated in proliferating endothelial cells and to be strongly expressed in the neovasculature of a wide range of solid tumours [55]. In non-malignant adult tissue vessels, including pre-neoplastic lesions, endoglin expression is weaker than in tumour vessels and often restricted to capillaries [55]. According to Balza and co-workers [56], although endoglin is upregulated in tumour vasculature, its expression is not restricted to tumour tissues, and their findings showed a widespread distribution of the antigen in vessels of normal adult tissues. Therefore, further detailed analyses are needed in view of endoglin-specific antibody applications in tumour diagnosis.

CONCLUSION

In summary, it remains to be determined how widespread the association between OPN and patient survival will prove to be, not only in breast but in other metastatic carcinomas. Thus far pilot studies on a small group of lymph node-negative breast cancer [16] and gastric cancer [17] patients have shown a positive association with patient demise and disease progression, respectively, whereas in ovarian cancers a surprising association with low malignant tumours has been reported [57]. With this work, we showed, in one group of invasive human breast cancer cases, that no statistical significant association exists between OPN expression, major clinicopathological parameters and some of the commonly used molecular markers. Also, no correlation was found between OPN expression and angiogenesis as discussed above. Nevertheless, a strong tendency for higher proliferation rates was observed for individuals classified as OPN-positive. Therefore, although many studies have been recently published on OPN potential as a breast cancer biomarker, it is still not clear if it can provide important diagnosis information, evaluate treatment effects or assess the potential for metastatic disease in patients.

ACKNOWLEDGEMENTS

The F.C.T. (Fundação para a Ciência e a Tecnologia - Portugal) provided financial support for LR through a postdoctoral research grant SFRH/BPD/26064/2005 and to NL through a research grant POCTI/CBO/45157/2002.

REFERENCES


Received: August 8, 2008
Revised: November 11, 2008
Accepted: December 17, 2008

© Rodrigues et al.; Licensee Bentham Open.
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.